Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Photoq3 Inc. has 2 pending office actions in Biotechnology & Pharmaceuticals. The matters are distributed across 2 examiners and 2 art units, indicating that prosecution activity is not concentrated within a single examination channel. That structure gives counsel more than one examiner relationship and may require separate responses tailored to different technical or procedural positions.
PUTTLITZ, KARL J is the busiest examiner, with 1 pending matter. The available distribution shows that this examiner handles only part of the outstanding work, while the remaining matter is assigned elsewhere. Counsel should therefore track response deadlines and claim strategy at the application level rather than treating the portfolio as a single examiner matter.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PUTTLITZ, KARL J | 1 | 69.2% | +18.5% |
| SANG, HONG | 1 | 54.9% | +62.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17916642 | MEDICAMENT FOR KILLING TUMOR CELLS | SANG, HONG | 57d |
| 18694587 | MEDICAMENT FOR KILLING TUMOR CELLS | PUTTLITZ, KARL J | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17916642 | MEDICAMENT FOR KILLING TUMOR CELLS | SANG, HONG | 57d |
| 18694587 | MEDICAMENT FOR KILLING TUMOR CELLS | PUTTLITZ, KARL J | — |
| Art Unit | Apps |
|---|---|
| 1646 | 1 |
| 1645 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18694587 | MEDICAMENT FOR KILLING TUMOR CELLS | PUTTLITZ, KARL J | 1646 | §103§112 | Non-Final OA | — | Pending | Mar 22, 2024 |
| 17916642 | MEDICAMENT FOR KILLING TUMOR CELLS | SANG, HONG | 1645 | §103§112 | Final Rejection | 57d | Pending | Oct 03, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialPhotoq3 Inc. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Karl J Puttlitz has the most, with 1 of Photoq3 Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
